MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...

Honda now joins the sweep of rebrands with a logo that wouldn’t look out of place on the outside of a spaceship or worn as a ...

Overgrown forests and climate change are making record-breaking wildfires commonplace, but land managers can “treat” forests to change their behavior during burns. Firefighters try to protect homes ...